vimarsana.com

Latest Breaking News On - Lyme phase - Page 1 : vimarsana.com

Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates

07.05.2024 - Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates Q1 financial highlights Total revenues of €32.8 million, including sales of €32.1 million, on track to meet anticipated full year guidance .

United kingdomUnited statesRabipur rabavertJoshua drummInstituto butantanFda tropical disease priority review voucher programCoalition for epidemic preparedness innovationsUs centers for diseaseGlobal communicationsUs advisory committee on immunization practicesDeerfield management companyExchange commissionThird partyPriority review voucherEuronext parisFinancial reports

Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates Q1 financial highlights Total revenues of €32.8 million, including sales of €32.1.

United kingdomUnited statesJoshua drummInstituto butantanFda tropical disease priority review voucher programExchange commissionDeerfield management companyGlobal communicationsTropical disease priority review voucher programUs centers for diseaseCoalition for epidemic preparedness innovationsUs advisory committee on immunization practicesThird partyValneva reports first quarterPriority review voucherEuronext paris

Valneva SE (NASDAQ:VALN) Q3 2022 Earnings Call Transcript

Operator: Good day, and thank you for standing by. Welcome to the Valneva Reports Nine-Month 2022 Results and Provides Corporate Updates Call. At this time, all participants are in a listen-only mode.

United kingdomUnited statesPeter buhlerVivalis intercellSamir devaniMaury raycroftInstituto butantanThomas lingelbachUs department of defenseLife insurance companiesCall transcript novemberValneva reports nine monthProvides corporate updatesLyme phaseFast trackPhantom share programs

vimarsana © 2020. All Rights Reserved.